STAT+: ARPA-H launches $160 million effort to develop custom gene editing drugs
2026-07-09 15:00
601 views
Jean-Christophe VERHAEGEN / AFP via Getty Images
By Jason MastJuly 9, 2026
General Assignment Reporter
Jason Mast[email protected]Jason is a general assignment reporter, with particular focus on genet...
Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77.
ARPA-H, the U.S.’ “moonshot” agency for health research, announced Thursday that it will spend up to $160 million to push forward custom gene editing treatments for a spate of rare diseases.
The program, called THRIVE, will back seven different teams pursuing various groups of conditions affecting different organ systems.
Each team has a deadline of starting clinical trials by year three of the program, although some may start much sooner.
Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77.
